Skip to main content

Table 7 OS analysis for patients after PSM

From: The platelet to lymphocyte ratio is a potential inflammatory marker predicting the effects of adjuvant chemotherapy in patients with stage II colorectal cancer

Characteristics

 

RMSTb (95%CI)

HRc (95%CI)

P valuea

Interaction p

Non- Chemotherapy

Chemotherapy

Total

–

53.3 (50.9–55.2)

56.0 (54.0–57.4)

0.584 (0.333–1.025)

0.058

–

Sex

Male

52.0 (48.1–54.6)

55.9 (53.2–57.6)

0.487 (0.240–0.991)

0.042

0.157

Female

55.0 (50.7–57.2)

56.1 (52.8–58.0)

0.787 (0.310–2.003)

0.615

 

Age (years)

≤55

53.8 (46.6–57.2)

56.6 (50.7–59.0)

0.536 (0.128–2.251)

0.386

0.574

56–60

54.6 (45.6–58.2)

57.1 (48.8–59.2)

0.584 (0.097–3.499)

0.551

 

61–65

53.2 (45.7–57.0)

55.6 (49.8–58.3)

0.641 (0.171–2.403)

0.505

 

66–70

54.2 (47.2–57.3)

57.5 (52.6–59.1)

0.392 (0.098–1.576)

0.170

 

> 70

52.0 (46.9–55.2)

53.9 (49.1–56.9)

0.748 (0.305–1.830)

0.522

 

Location

Rectum

52.4 (48.6–55.0)

54.6 (51.2–56.8)

0.725 (0.366–1.435)

0.353

0.283

Colon

54.5 (50.6–56.9)

57.5 (54.9–58.9)

0.428 (0.158–1.163)

0.086

 

Size (cm)

≤5.0

54.3 (50.8–56.6)

56.7 (54.0–58.1)

0.548 (0.236–1.269)

0.153

0.165

> 5.0

52.6 (48.6–55.4)

55.1 (51.8–57.3)

0.672 (0.312–1.449)

0.307

 

Differentiation

Well-moderate

53.5 (50.8–55.4)

56.1 (54.0–57.5)

0.570 (0.315–1.031)

0.059

0.702

Poor

50.5 (36.8–56.9)

53.8 (39.9–58.2)

0.711 (0.117–4.339)

0.708

 

T category

3

58.1 (54.7–59.3)

57.3 (54.2–58.9)

1.439 (0.342–6.045)

0.618

0.072

4

50.9 (47.1–53.4)

55.2 (52.1–57.0)

0.501 (0.267–0.939)

0.027

 

CEAd (ng/mL)

< 5

55.2 (51.8–57.1)

57.3 (54.4–58.7)

0.557 (0.219–1.414)

0.211

0.790

≥5

52.4 (46.8–55.7)

55.0 (51.0–57.4)

0.641 (0.265–1.552)

0.320

 

Examined lymph nodes

< 12

50.7 (44.5–54.8)

51.7 (46.5–55.1)

0.898 (0.381–2.118)

0.806

0.322

≥12

54.1 (51.4–56.0)

57.5 (55.5–58.7)

0.404 (0.185–0.882)

0.018

 

PLRe

≤130

55.3 (51.8–57.4)

54.9 (52.0–56.8)

1.080 (0.495–2.355)

0.847

0.038

> 130

51.3 (47.2–54.2)

57.6 (54.2–59.0)

0.272 (0.102–0.726)

0.005

 
  1. a P value of the log-rank test
  2. b RMST: the restricted mean survival time
  3. c HR: Hazard Ratio, chemotherapy patients vs. non-chemotherapy patients
  4. d CEA: carcinoembryonic antigen
  5. e PLR: platelet to lymphocyte ratio